Disease Site Groups
The charge to the UFHCC DSGs is to provide an integrated, multidisciplinary approach to guide in the selection, prioritization and conduct of high quality cancer research studies. Each clinical DSG has at least one designated clinical and research leader while the research based DSGs have research co-leaders.
Each DSG is charged with establishing priorities within the framework described below.
- Collaborating with UFHCC members and other UFHCC Research Programs to develop areas of research with potential impact in the field of study,
- Reviewing initial study concepts for UF investigator-initiated trials (IITs),
- Review and endorsement of all new trials which are to be opened,
- Ongoing review and internal prioritization of interventional studies,
- Performing ongoing review of the DSG’s research portfolio, including a review of accrual rates for existing trials,
- Optimizing population subgroup recruitment, including increasing both gender and racial/ethnic diversity, with particular emphasis on the UFHCC catchment area,
- Maintaining a priority list of pending and active protocols for their research portfolio.
All new interventional trials must be reviewed and approved by the applicable group of record prior to SRMC submission. For example, any clinical trials conducted in breast cancer must be vetted through the breast DSG. DSGs are responsible for ensuring that adequate resources are available to conduct the study. The sponsoring DSG research leader must attest to the projected annual accrual, allocation of UFHCC Clinical Research Office (CRO) resources, presence or absence of competing studies, and overall endorsement of support from the group.
For information related to the DSGs, please contact Timmy Guinn, research administrator, at email@example.com or 352.294.8679; or Judy Walsh, research administrator, at firstname.lastname@example.org or 352.294.8615.